ElsaLys Biotech, a biopharmaceutical company dedicated to the development of "best-in-disease" therapeutic antibodies for oncology and ophthalmology, announces today that it has completed the first instalment of a € 5 million fundraising.
This first instalment of € 2.7 million was subscribed by Sofimac Partners, already a shareholder, and by IM Europe, a subsidiary of Institut Mérieux and Crédit Agricole Création.
This new funding allows ElsaLys Biotech to support the development of its antibodies, including its anti-CD160 developed for ophthalmology and oncology indications. With the completion of a toxicology study, the anti-CD160 programme for ophthalmology would thus reach an important milestone in its preclinical evaluation. This funding will also allow its two other antibodies developed for oncology - anti-CD160 and anti-TYRO3 - to reach preclinical proof of concept.